 IBTimes.co.uk |
AstraZeneca Loses US Patent on Asthma Drug
IBTimes.co.uk Apotex and Actavis had received approval from the US Food and Drugs Administration (FDA), but they are yet to launch generic versions of the medicine, which is used to control and prevent asthma symptoms in children aged between 12 months to 8 years. US court blow for AstraZeneca on asthma drug AstraZeneca to contest US court ruling over asthma medicine AstraZeneca loses US drug patent judgment |
View full post on asthma – Google News